Dr. Thomas A. Abrams, Senior Physician and Assistant Professor of Medicine at Harvard Medical School discusses whether the POLO Trial with olaparib in metastatic pancreatic cancer is practice changing with respect to patients.
Advertisement
[the_ad id="32629"]